CeaproTSXV: CZO

Ceapro announces 2006 first quarter financial results

· Issued by Ceapro via CNW
EDMONTON, May 29 /CNW/ - Ceapro Inc. (TSX-V: CZO) today released its
first quarter financial results for 2006. Ceapro produced solid financial
results with strong performance in sales. Sales increased by 131% to $899,000
in the first three months. Income from operations increased $131,000 to
$19,000 in the first quarter; however, research and product development costs
affected the overall financial results producing a net loss of $51,000 for the
three month period ending March 31, 2005.
"We are satisfied with our quarterly financial results especially the
continued growth of revenues which maintains the strong positive trend
achieved in 2005." stated Dr. Mark Redmond, President and CEO of Ceapro. "We
continue to focus on growth by increasing sales and developing new
opportunities, with emphasis placed on securing new pharmaceutical customers
to use our active ingredients and launching our veterinary products in the
United States. We are introducing CeaProve(R) to Canadian corporations, as
part of corporate wellness programs, and to several countries for point-of-
care diagnosis of diabetes and impaired glucose tolerance."
We have realized a significant increase in sales of oat extracts most
notably to Johnson and Johnson, for use in line-extensions to the Aveeno(R)
brand of skincare products. Brennen Medical has also increased their orders
for beta glucan for use in the wound-care market, and Genzyme has introduced a
beta glucan-based hernia treatment. Ceapro's technical team continues to
develop these markets by working with new customers in developing over-the-
counter products containing pharmaceutical beta glucan.
In our latest annual report we announced our intention to open the US
market for our animal health products. Our market strategy calls for
distribution and promotion through a regional network of suppliers. In
preparation for entering this market we are developing a comprehensive brand
strategy to create a single name for the US product range, which will create
brand equity and a unified marketing message across the country. We anticipate
making further US market announcements later this year.
We expect the prestigious Frost & Sullivan Innovative Product award for
CeaProve(R) to establish a global profile for Ceapro. The associated coverage
will be an opportunity to focus on CeaProve(R), and provide a stage from which
to present CeaProve(R) to healthcare providers. This award can open doors for
Ceapro to fulfill its goal to enhance health internationally, specifically
addressing the global diabetes epidemic.
Our outlook continues to be positive. We are encouraged by continued
strong second quarter sales and anticipate further revenue growth throughout
2006. We expect the expansion of sales to existing customers, and the
introduction of new products to new customers to further increase sales of
both active ingredients and veterinary therapeutic products. Ceapro expects to
undertake further expansion of manufacturing capacity to meet this increased
demand.

About Ceapro Inc.

Ceapro Inc is a Canadian growth stage biotechnology company. Ceapro's
core technology is the extraction of functional, active ingredients from
plants and other renewable resources. We add further value to our extracts by
manufacturing medical and therapeutic products, and by supporting the use of
our extracts in products for human and animal health. We have also introduced
health and wellness services employing our CeaProve(R) diagnostic technology.
Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol CZO.
To learn more about Ceapro, visit our website at www.ceapro.com. Shares
Outstanding: 37,098,670.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the forward-
looking statements contained herein are reasonable, it can give no assurance
that the Company's expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement.

<<

CEAPRO INC.
Consolidated Balance Sheets
                                                  March 31   December 31
                                                      2006          2005
                                                (Unaudited)     (Audited)
-------------------------------------------------------------------------
ASSETS
CURRENT ASSETS
  Cash                                         $   758,256   $   438,045
  Accounts receivable                              872,211       982,347
  Inventories                                      183,578       228,158
  Prepaid expenses and deposits                     65,653        90,761
-------------------------------------------------------------------------

                                                 1,879,698     1,739,311
PROPERTY AND EQUIPMENT (NET OF
 ACCUMULATED AMORTIZATION)                         654,340       679,623
-------------------------------------------------------------------------

                                               $ 2,534,038   $ 2,418,934
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES
CURRENT LIABILITIES
  Accounts payable and accrued liabilities     $   472,750   $   284,863
  Deferred revenue                                 114,644       229,676
  Callable debt                                     70,590        81,584
  Current portion of long-term debt                 31,293        33,519
  Current portion of royalties payable             206,335       106,508
-------------------------------------------------------------------------

                                                   895,612       736,150

DEFERRED ROYALTY REVENUE                           446,727       457,000
EMPLOYEE FUTURE BENEFITS OBLIGATION                172,846       159,946
LONG-TERM DEBT                                     430,851       436,731
ROYALTIES PAYABLE                                  167,770       167,770
-------------------------------------------------------------------------
                                                 2,113,806     1,957,597
-------------------------------------------------------------------------
SHAREHOLDERS' EQUITY

SHARE CAPITAL                                    2,421,524     2,414,830
CONTRIBUTED SURPLUS                                110,375       106,888
DEFICIT                                         (2,111,667)   (2,060,381)
-------------------------------------------------------------------------

                                                   420,232       461,337
-------------------------------------------------------------------------

                                               $ 2,534,038   $ 2,418,934
-------------------------------------------------------------------------
-------------------------------------------------------------------------



CEAPRO INC.
Consolidated Statements of Net (Loss) Income and Deficit
Unaudited

                                                Three Months and Quarter
                                                          Ended March 31
                                                      2006          2005
-------------------------------------------------------------------------
Revenue
  Sales                                        $   899,199   $   388,528
  Cost of goods sold                               437,113       224,303
-------------------------------------------------------------------------

  Gross margin                                     462,086       164,225
  Royalties, licenses, and product
   development fees                                      -        80,000
-------------------------------------------------------------------------

                                                   462,086       244,225
-------------------------------------------------------------------------
Expenses
  General and administration                       235,741       202,590
  Royalties                                         89,553        51,922
  Sales and marketing                               70,216        51,675
  Amortization                                      35,732        38,895
  Interest on long-term debt                        10,379         7,357
  Interest on callable debt and other                1,532         3,806
-------------------------------------------------------------------------

                                                   443,153       356,245
-------------------------------------------------------------------------
Income (loss) from operations                       18,933      (112,020)
-------------------------------------------------------------------------

Other income (expenses)
  Research and product development                 (71,356)      (44,202)
  Other income (expenses)                            1,137          (242)
-------------------------------------------------------------------------

                                                   (70,219)      (44,444)
-------------------------------------------------------------------------

NET (LOSS) INCOME FOR THE PERIOD                   (51,286)     (156,464)

Deficit, beginning of period                    (2,060,381)   (1,605,637)
-------------------------------------------------------------------------

Deficit, end of period                         $(2,111,667)  $(1,762,101)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Net (loss) income per share:
  Basic                                        $     (0.00)  $     (0.00)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
  Diluted                                      $     (0.00)  $     (0.00)
-------------------------------------------------------------------------
-------------------------------------------------------------------------



CEAPRO INC.
Consolidated Statements of Cash Flows
Unaudited

                                                Three Months and Quarter
                                                          Ended March 31
                                                      2006          2005
-------------------------------------------------------------------------

Operating Activities
  Net (loss) income for the period             $   (51,286)  $  (156,464)
  Items not affecting cash
    Amortization                                    35,732        38,895
    Employee future benefits obligation             12,900         3,000
    Recognition of deferred royalty revenue        (10,273)            -
    Stock based compensation                         4,556         1,226
-------------------------------------------------------------------------

                                                    (8,371)     (113,343)

Changes in Non-Cash Working Capital Items
  Accounts receivable                              110,136      (167,453)
  Inventories                                       44,580        32,272
  Prepaid expenses and deposits                     25,108         5,129
  Accounts payable and accrued liabilities         187,887       123,351
  Deferred revenue                                (115,032)      (80,000)
-------------------------------------------------------------------------

                                                   244,308      (200,044)
-------------------------------------------------------------------------

Investing Activities
  Purchase of property and equipment               (10,449)      (48,321)
  Restricted cash for the purchase of property
   and equipment                                         -        38,628
-------------------------------------------------------------------------

                                                   (10,449)       (9,693)
-------------------------------------------------------------------------
Financing Activities
  Repayment of long-term debt                       (8,106)       (4,965)
  Repayment of callable debt                       (10,994)       (9,790)
  Proceeds from issuance of share capital                -       204,800
  Proceeds from exercise of options                  5,625         9,500
  Increase (decrease) in royalties payable          99,827        51,921
-------------------------------------------------------------------------

                                                    86,352       251,466
-------------------------------------------------------------------------

Increase (decrease) in cash                        320,211        41,729
Cash at beginning of period                        438,045        96,266
-------------------------------------------------------------------------

Cash at end of period                          $   758,256   $   137,995
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Supplementary information:
  Interest paid                                $    11,911   $    12,659
  Royalties paid                               $         -   $         -

>>
%SEDAR: 00010110E

Ceapro on 6ix

Story so far

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases